Receptor, Fibroblast Growth Factor, Type 2
"Receptor, Fibroblast Growth Factor, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fibroblast growth factor receptor which contains three extracellular IMMUNOGLOBULIN I-SET DOMAINS and is expressed as two isoforms. One receptor isoform is expressed in the MESENCHYME and is activated by FIBROBLAST GROWTH FACTOR 2. A second isoform is expressed mainly by EPITHELIAL CELLS and is activated by FIBROBLAST GROWTH FACTOR 7 and FIBROBLAST GROWTH FACTOR 10. Mutation of the gene for fibroblast growth factor receptor 2 can result in craniosynostotic syndromes (e.g., APERT SYNDROME; and CROUZON SYNDROME).
Descriptor ID |
D051497
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.178 D12.776.543.750.630.441 D12.776.543.750.750.400.370.750
|
Concept/Terms |
Receptor, Fibroblast Growth Factor, Type 2- Receptor, Fibroblast Growth Factor, Type 2
- BEK Fibroblast Growth Factor Receptor
- BEK Protein Tyrosine Kinase
- Bek Fgf Receptor Kinase
- Fibroblast Growth Factor Receptor 2
- Bek-Related Fibroblast Growth Factor-Receptor-1
- Bek Related Fibroblast Growth Factor Receptor 1
- Fibroblast Growth Factor Receptors 2
- FGFR2 Protein
- CD332 Antigen
- Antigen, CD332
- BEK Fibroblast Growth Factor Receptor Kinase
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Fibroblast Growth Factor, Type 2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, Fibroblast Growth Factor, Type 2 [D08.811.913.696.620.682.725.400.178]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- Receptor, Fibroblast Growth Factor, Type 2 [D12.776.543.750.630.441]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Fibroblast Growth Factor [D12.776.543.750.750.400.370]
- Receptor, Fibroblast Growth Factor, Type 2 [D12.776.543.750.750.400.370.750]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Fibroblast Growth Factor, Type 2".
This graph shows the total number of publications written about "Receptor, Fibroblast Growth Factor, Type 2" by people in this website by year, and whether "Receptor, Fibroblast Growth Factor, Type 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
2014 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2017 | 3 | 1 | 4 |
2018 | 1 | 0 | 1 |
2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, Fibroblast Growth Factor, Type 2" by people in Profiles.
-
Erdafitinib for advanced urothelial carcinoma. Lancet Oncol. 2019 09; 20(9):e469.
-
Midface and upper airway dysgenesis in FGFR2-related craniosynostosis involves multiple tissue-specific and cell cycle effects. Development. 2018 10 05; 145(19).
-
Neuron and microglia/macrophage-derived FGF10 activate neuronal FGFR2/PI3K/Akt signaling and inhibit microglia/macrophages TLR4/NF-?B-dependent neuroinflammation to improve functional recovery after spinal cord injury. Cell Death Dis. 2017 10 05; 8(10):e3090.
-
A novel heterozygous mutation in FGFR2 gene causing Pfeiffer syndrome. Am J Med Genet A. 2017 10; 173(10):2838-2843.
-
Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors. Bioorg Med Chem Lett. 2017 08 15; 27(16):3782-3786.
-
Fibroblast growth factor 2 protects against renal ischaemia/reperfusion injury by attenuating mitochondrial damage and proinflammatory signalling. J Cell Mol Med. 2017 Nov; 21(11):2909-2925.
-
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017 03; 7(3):252-263.
-
Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Ann Surg Oncol. 2014 May; 21(5):1561-8.
-
Lens-forming competence in the epidermis of Xenopus laevis during development. J Exp Zool A Comp Exp Biol. 2005 Jan 01; 303(1):1-12.